Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PER2 | O15055 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249142 | 0.89 | CCR9 (0.36) | CCR9GRIA2 | |
| SCHEMBL20249205 | 0.85 | SIGMAR1 (0.41) | CYP11B2PIK3CAMTORPER2 | |
| SCHEMBL18291185 | 0.83 | CHRM1 (0.43) | CYP11B2PIK3CAMTORGRM2JAK2 | |
| SCHEMBL20249210 | 0.80 | L3MBTL1 (0.49) | CCR9GRIA2 | |
| SCHEMBL18291702 | 0.80 | CYP11B2 (0.43) | CYP11B2PIK3CAMTORGRM2JAK2 | |
| SCHEMBL20037864 | 0.80 | CYP11B2 (0.41) | CYP11B2PIK3CAMTORGRM2JAK2 | |
| SCHEMBL5737672 | 0.80 | POLB (0.47) | GRM2PER2JAK2 | |
| SCHEMBL29491140 | 0.79 | POLB (0.50) | CYP11B2PIK3CAMTORGRM2JAK2 | |
| SCHEMBL2739651 | 0.78 | HRH3 (0.51) | — | |
| SCHEMBL20249148 | 0.78 | CDK4 (0.40) | CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CYP11B2 1006/4885PIK3CA 108/4885MTOR 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.